메뉴 건너뛰기




Volumn 4, Issue 6, 2012, Pages 653-663

Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies

Author keywords

Antibody; Bispecific; CrossMab; DAF; Heavy chain; Heterodimerization; Knobs into holes; Light chain

Indexed keywords

ANGIOPOIETIN RECEPTOR ANTIBODY; ANTIBODY CONJUGATE; BEVACIZUMAB; BISPECIFIC ANTIBODY; CATUMAXOMAB; CETUXIMAB; CVX 241; DUAL ACTING ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; HETERODIMER; IMMUNOGLOBULIN F(AB')2 FRAGMENT; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; METMAB; RECEPTOR ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY;

EID: 84869783247     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.21379     Document Type: Review
Times cited : (174)

References (67)
  • 1
    • 77951586447 scopus 로고    scopus 로고
    • Strategies and challenges for the next generation of therapeutic antibodies
    • PMID:20414207
    • Beck A, Wurch T, Bailly C, Corvaia N. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010; 10:345-52; PMID:20414207; http://dx.doi.org/10.1038/nri2747
    • (2010) Nat Rev Immunol , vol.10 , pp. 345-352
    • Beck, A.1    Wurch, T.2    Bailly, C.3    Corvaia, N.4
  • 2
    • 79955666020 scopus 로고    scopus 로고
    • Introduction to current and future protein therapeutics: A protein engineering perspective
    • PMID:21371474
    • Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011; 317:1261-9; PMID:21371474; http://dx.doi.org/10.1016/j.yexcr.2011.02.013
    • (2011) Exp Cell Res , vol.317 , pp. 1261-1269
    • Carter, P.J.1
  • 3
    • 77951529848 scopus 로고    scopus 로고
    • Therapeutic antibodies for autoimmunity and inflammation
    • PMID:20414204
    • Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10:301-16; PMID:20414204; http://dx.doi.org/10.1038/nri2761
    • (2010) Nat Rev Immunol , vol.10 , pp. 301-316
    • Chan, A.C.1    Carter, P.J.2
  • 4
    • 34248382009 scopus 로고    scopus 로고
    • Bispecific antibodies: Molecules that enable novel therapeutic strategies
    • PMID:17496428
    • Fischer N, Léger O. Bispecific antibodies: molecules that enable novel therapeutic strategies. Pathobiology 2007; 74:3-14; PMID:17496428; http://dx.doi.org/10.1159/000101046
    • (2007) Pathobiology , vol.74 , pp. 3-14
    • Fischer, N.1    Léger, O.2
  • 6
    • 79957452852 scopus 로고    scopus 로고
    • A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo
    • PMID:21613622
    • Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, et al. A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci Transl Med 2011; 3:84ra43; PMID:21613622; http://dx.doi.org/10.1126/ scitranslmed.3002254
    • (2011) Sci Transl Med , vol.3
    • Atwal, J.K.1    Chen, Y.2    Chiu, C.3    Mortensen, D.L.4    Meilandt, W.J.5    Liu, Y.6
  • 7
    • 79959312575 scopus 로고    scopus 로고
    • Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival
    • PMID:21576633
    • Topp MS, Kufer P, Gökbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29:2493-8; PMID:21576633; http://dx.doi.org/10.1200/JCO.2010.32.7270
    • (2011) J Clin Oncol , vol.29 , pp. 2493-2498
    • Topp, M.S.1    Kufer, P.2    Gökbuget, N.3    Goebeler, M.4    Klinger, M.5    Neumann, S.6
  • 8
    • 77951596808 scopus 로고    scopus 로고
    • Catumaxomab: Clinical development and future directions
    • PMID:20190561
    • Linke R, Klein A, Seimetz D. Catumaxomab: clinical development and future directions. MAbs 2010; 2:129-36; PMID:20190561; http://dx.doi.org/10.4161/ mabs.2.2.11221
    • (2010) MAbs , vol.2 , pp. 129-136
    • Linke, R.1    Klein, A.2    Seimetz, D.3
  • 9
    • 80155150449 scopus 로고    scopus 로고
    • Buy buy bispecific antibodies
    • PMID:22037028
    • Holmes D. Buy buy bispecific antibodies. Nat Rev Drug Discov 2011; 10:798-800; PMID:22037028; http://dx.doi.org/10.1038/nrd3581
    • (2011) Nat Rev Drug Discov , vol.10 , pp. 798-800
    • Holmes, D.1
  • 10
    • 84859409756 scopus 로고    scopus 로고
    • Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3
    • PMID:22248472
    • McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther 2012; 11:582-93; PMID:22248472; http://dx.doi.org/10.1158/1535-7163.MCT-11- 0820
    • (2012) Mol Cancer Ther , vol.11 , pp. 582-593
    • McDonagh, C.F.1    Huhalov, A.2    Harms, B.D.3    Adams, S.4    Paragas, V.5    Oyama, S.6
  • 11
    • 78651091039 scopus 로고    scopus 로고
    • Chemical generation of bispecific antibodies
    • PMID:21149738
    • Doppalapudi VR, Huang J, Liu D, Jin P, Liu B, Li L, et al. Chemical generation of bispecific antibodies. Proc Natl Acad Sci U S A 2010; 107:22611-6; PMID:21149738; http://dx.doi.org/10.1073/pnas.1016478108
    • (2010) Proc Natl Acad Sci U S A , vol.107 , pp. 22611-22616
    • Doppalapudi, V.R.1    Huang, J.2    Liu, D.3    Jin, P.4    Liu, B.5    Li, L.6
  • 12
    • 77955976111 scopus 로고    scopus 로고
    • Stability engineering of scFvs for the development of bispecific and multivalent antibodies
    • PMID:20457695
    • Miller BR, Demarest SJ, Lugovskoy A, Huang F, Wu X, Snyder WB, et al. Stability engineering of scFvs for the development of bispecific and multivalent antibodies. Protein Eng Des Sel 2010; 23:549-57; PMID:20457695; http://dx.doi.org/10.1093/protein/gzq028
    • (2010) Protein Eng des Sel , vol.23 , pp. 549-557
    • Miller, B.R.1    Demarest, S.J.2    Lugovskoy, A.3    Huang, F.4    Wu, X.5    Snyder, W.B.6
  • 13
    • 50249132634 scopus 로고    scopus 로고
    • Antibody therapeutics, antibody engineering, and the merits of protein stability
    • PMID:18729019
    • Demarest SJ, Glaser SM. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr Opin Drug Discov Devel 2008; 11:675-87; PMID:18729019
    • (2008) Curr Opin Drug Discov Devel , vol.11 , pp. 675-687
    • Demarest, S.J.1    Glaser, S.M.2
  • 14
    • 79955658810 scopus 로고    scopus 로고
    • Rational engineering of antibody therapeutics targeting multiple oncogene pathways
    • PMID:21393992
    • Fitzgerald J, Lugovskoy A. Rational engineering of antibody therapeutics targeting multiple oncogene pathways. MAbs 2011; 3:299-309; PMID:21393992; http://dx.doi.org/10.4161/mabs.3.3.15299
    • (2011) MAbs , vol.3 , pp. 299-309
    • Fitzgerald, J.1    Lugovskoy, A.2
  • 15
    • 79957683054 scopus 로고    scopus 로고
    • Bispecific digoxigenin-binding antibodies for targeted payload delivery
    • PMID:21536919
    • Metz S, Haas AK, Daub K, Croasdale R, Stracke J, Lau W, et al. Bispecific digoxigenin-binding antibodies for targeted payload delivery. Proc Natl Acad Sci U S A 2011; 108:8194-9; PMID:21536919; http://dx.doi.org/10.1073/pnas. 1018565108
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 8194-8199
    • Metz, S.1    Haas, A.K.2    Daub, K.3    Croasdale, R.4    Stracke, J.5    Lau, W.6
  • 16
    • 79955548494 scopus 로고    scopus 로고
    • Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains
    • PMID:21300827
    • Schanzer J, Jekle A, Nezu J, Lochner A, Croasdale R, Dioszegi M, et al. Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains. Antimicrob Agents Chemother 2011; 55:2369-78; PMID:21300827; http://dx.doi.org/10.1128/ AAC.00215-10
    • (2011) Antimicrob Agents Chemother , vol.55 , pp. 2369-2378
    • Schanzer, J.1    Jekle, A.2    Nezu, J.3    Lochner, A.4    Croasdale, R.5    Dioszegi, M.6
  • 17
    • 80052580966 scopus 로고    scopus 로고
    • Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design
    • PMID:21814039
    • Digiammarino EL, Harlan JE, Walter KA, Ladror US, Edalji RP, Hutchins CW, et al. Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design. MAbs 2011; 3:487-94; PMID:21814039; http://dx.doi.org/10.4161/mabs.3.5.16326
    • (2011) MAbs , vol.3 , pp. 487-494
    • Digiammarino, E.L.1    Harlan, J.E.2    Walter, K.A.3    Ladror, U.S.4    Edalji, R.P.5    Hutchins, C.W.6
  • 18
    • 35948977323 scopus 로고    scopus 로고
    • Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin
    • PMID:17934452
    • Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7; PMID:17934452; http://dx.doi.org/10.1038/nbt1345
    • (2007) Nat Biotechnol , vol.25 , pp. 1290-1297
    • Wu, C.1    Ying, H.2    Grinnell, C.3    Bryant, S.4    Miller, R.5    Clabbers, A.6
  • 19
    • 39449129555 scopus 로고    scopus 로고
    • Construction of optimized bispecific antibodies for selective activation of the death receptor CD95
    • PMID:18281499
    • Herrmann T, Grosse-Hovest L, Otz T, Krammer PH, Rammensee HG, Jung G. Construction of optimized bispecific antibodies for selective activation of the death receptor CD95. Cancer Res 2008; 68:1221-7; PMID:18281499; http://dx.doi.org/10.1158/0008-5472.CAN-07-6175
    • (2008) Cancer Res , vol.68 , pp. 1221-1227
    • Herrmann, T.1    Grosse-Hovest, L.2    Otz, T.3    Krammer, P.H.4    Rammensee, H.G.5    Jung, G.6
  • 20
    • 79960650492 scopus 로고    scopus 로고
    • A novel redox method for rapid production of functional bispecific antibodies for use in early pilot studies
    • PMID:21811628
    • Carlring J, De Leenheer E, Heath AW. A novel redox method for rapid production of functional bispecific antibodies for use in early pilot studies. PLoS One 2011; 6:e22533; PMID:21811628; http://dx.doi.org/10.1371/journal.pone. 0022533
    • (2011) PLoS One , vol.6
    • Carlring, J.1    De Leenheer, E.2    Heath, A.W.3
  • 21
  • 22
    • 0024350251 scopus 로고
    • Hybrid antibodies in cancer diagnosis and therapy
    • PMID:2693537
    • Ménard S, Canevari S, Colnaghi MI. Hybrid antibodies in cancer diagnosis and therapy. Int J Biol Markers 1989; 4:131-4; PMID:2693537
    • (1989) Int J Biol Markers , vol.4 , pp. 131-134
    • Ménard, S.1    Canevari, S.2    Colnaghi, M.I.3
  • 23
    • 0028227751 scopus 로고
    • Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells
    • PMID:8171337
    • Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994; 264:833-5; PMID:8171337; http://dx.doi.org/10.1126/science. 8171337
    • (1994) Science , vol.264 , pp. 833-835
    • Renner, C.1    Jung, W.2    Sahin, U.3    Denfeld, R.4    Pohl, C.5    Trümper, L.6
  • 24
    • 0029063312 scopus 로고
    • Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies
    • PMID:7602098
    • Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 1995; 155:219-25; PMID:7602098
    • (1995) J Immunol , vol.155 , pp. 219-225
    • Lindhofer, H.1    Mocikat, R.2    Steipe, B.3    Thierfelder, S.4
  • 25
    • 0033178740 scopus 로고    scopus 로고
    • Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing
    • PMID:10415020
    • Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999; 163:1246-52; PMID:10415020
    • (1999) J Immunol , vol.163 , pp. 1246-1252
    • Zeidler, R.1    Reisbach, G.2    Wollenberg, B.3    Lang, S.4    Chaubal, S.5    Schmitt, B.6
  • 26
    • 77953665930 scopus 로고    scopus 로고
    • Structural and functional characterization of the trifunctional antibody catumaxomab
    • PMID:20418662
    • Chelius D, Ruf P, Gruber P, Plöscher M, Liedtke R, Gansberger E, et al. Structural and functional characterization of the trifunctional antibody catumaxomab. MAbs 2010; 2:309-19; PMID:20418662; http://dx.doi.org/10.4161/mabs. 2.3.11791
    • (2010) MAbs , vol.2 , pp. 309-319
    • Chelius, D.1    Ruf, P.2    Gruber, P.3    Plöscher, M.4    Liedtke, R.5    Gansberger, E.6
  • 27
    • 0035251453 scopus 로고    scopus 로고
    • Bispecific human IgG by design
    • PMID:11223065
    • Carter P. Bispecific human IgG by design. J Immunol Methods 2001; 248:7-15; PMID:11223065; http://dx.doi.org/10.1016/S0022-1759(00)00339-2
    • (2001) J Immunol Methods , vol.248 , pp. 7-15
    • Carter, P.1
  • 29
    • 0030909820 scopus 로고    scopus 로고
    • Remodeling domain interfaces to enhance heterodimer formation
    • PMID:9098887
    • Zhu Z, Presta LG, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997; 6:781-8; PMID:9098887; http://dx.doi.org/10.1002/pro.5560060404
    • (1997) Protein Sci , vol.6 , pp. 781-788
    • Zhu, Z.1    Presta, L.G.2    Zapata, G.3    Carter, P.4
  • 30
    • 0029946383 scopus 로고    scopus 로고
    • 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization
    • PMID:8844834
    • Ridgway JB, Presta LG, Carter P. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 1996; 9:617-21; PMID:8844834; http://dx.doi.org/10.1093/protein/9.7.617
    • (1996) Protein Eng , vol.9 , pp. 617-621
    • Ridgway, J.B.1    Presta, L.G.2    Carter, P.3
  • 31
    • 0031552589 scopus 로고    scopus 로고
    • Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library
    • PMID:9231898
    • Atwell S, Ridgway JB, Wells JA, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol 1997; 270:26-35; PMID:9231898; http://dx.doi.org/10.1006/jmbi.1997.1116
    • (1997) J Mol Biol , vol.270 , pp. 26-35
    • Atwell, S.1    Ridgway, J.B.2    Wells, J.A.3    Carter, P.4
  • 32
    • 49249100382 scopus 로고    scopus 로고
    • MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival
    • PMID:18519697
    • Jin H, Yang R, Zheng Z, Romero M, Ross J, Bou-Reslan H, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res 2008; 68:4360-8; PMID:18519697; http://dx.doi.org/10.1158/0008-5472.CAN-07-5960
    • (2008) Cancer Res , vol.68 , pp. 4360-4368
    • Jin, H.1    Yang, R.2    Zheng, Z.3    Romero, M.4    Ross, J.5    Bou-Reslan, H.6
  • 33
    • 33750683969 scopus 로고    scopus 로고
    • A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo
    • PMID:17062691
    • Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, et al. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006; 12:6144-52; PMID:17062691; http://dx.doi.org/10. 1158/1078-0432.CCR-05-1418
    • (2006) Clin Cancer Res , vol.12 , pp. 6144-6152
    • Martens, T.1    Schmidt, N.O.2    Eckerich, C.3    Fillbrandt, R.4    Merchant, M.5    Schwall, R.6
  • 34
    • 80555135913 scopus 로고    scopus 로고
    • Role of MetMAb (OA-5D5) in c-MET active lung malignancies
    • PMID:22047509
    • Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther 2011; 11:1655-62; PMID:22047509; http://dx.doi.org/10.1517/14712598.2011.626762
    • (2011) Expert Opin Biol Ther , vol.11 , pp. 1655-1662
    • Surati, M.1    Patel, P.2    Peterson, A.3    Salgia, R.4
  • 35
    • 84869753306 scopus 로고    scopus 로고
    • Methods for producing polypeptides by regulating polypeptide association
    • WO2006106905
    • Igawa T, Tsunoda H. Methods for producing polypeptides by regulating polypeptide association. WO2006106905. 2006
    • (2006)
    • Igawa, T.1    Tsunoda, H.2
  • 36
    • 77953485268 scopus 로고    scopus 로고
    • Enhancing antibody Fc heterodimer formation through electrostatic steering effects: Applications to bispecific molecules and monovalent IgG
    • PMID:20400508
    • Gunasekaran K, Pentony M, Shen M, Garrett L, Forte C, Woodward A, et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem 2010; 285:19637-46; PMID:20400508; http://dx.doi.org/10.1074/jbc.M110.117382. 22123055
    • (2010) J Biol Chem , vol.285 , pp. 19637-19646
    • Gunasekaran, K.1    Pentony, M.2    Shen, M.3    Garrett, L.4    Forte, C.5    Woodward, A.6
  • 37
    • 81255210896 scopus 로고    scopus 로고
    • A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens
    • PMID:22123055
    • Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 2011; 3:546-57.; PMID:22123055; http://dx.doi.org/10.4161/mabs.3.6.18123
    • (2011) MAbs , vol.3 , pp. 546-557
    • Moore, G.L.1    Bautista, C.2    Pong, E.3    Nguyen, D.H.4    Jacinto, J.5    Eivazi, A.6
  • 38
    • 77954628740 scopus 로고    scopus 로고
    • SEEDbodies: Fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies
    • PMID:20299542
    • Davis JH, Aperlo C, Li Y, Kurosawa E, Lan Y, Lo KM, et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel 2010; 23:195-202; PMID:20299542; http://dx.doi.org/10.1093/protein/gzp094
    • (2010) Protein Eng des Sel , vol.23 , pp. 195-202
    • Davis, J.H.1    Aperlo, C.2    Li, Y.3    Kurosawa, E.4    Lan, Y.5    Lo, K.M.6
  • 39
    • 79955440692 scopus 로고    scopus 로고
    • Therapeutic assessment of SEED: A new engineered antibody platform designed to generate mono- And bispecific antibodies
    • PMID:21498564
    • Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, et al. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 2011; 24:447-54; PMID:21498564; http://dx.doi.org/10.1093/protein/gzq123
    • (2011) Protein Eng des Sel , vol.24 , pp. 447-454
    • Muda, M.1    Gross, A.W.2    Dawson, J.P.3    He, C.4    Kurosawa, E.5    Schweickhardt, R.6
  • 40
    • 0027442660 scopus 로고
    • Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli
    • N Y PMID:7764189
    • Pack P, Kujau M, Schroeckh V, Knüpfer U, Wenderoth R, Riesenberg D, et al. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y) 1993; 11:1271-7; PMID:7764189
    • (1993) Biotechnology , vol.11 , pp. 1271-1277
    • Pack, P.1    Kujau, M.2    Schroeckh, V.3    Knüpfer, U.4    Wenderoth, R.5    Riesenberg, D.6
  • 41
    • 0026567963 scopus 로고
    • Formation of a bispecific antibody by the use of leucine zippers
    • PMID:1531669
    • Kostelny SA, Cole MS, Tso JY. Formation of a bispecific antibody by the use of leucine zippers. J Immunol 1992; 148:1547-53; PMID:1531669
    • (1992) J Immunol , vol.148 , pp. 1547-1553
    • Kostelny, S.A.1    Cole, M.S.2    Tso, J.Y.3
  • 42
    • 84869815266 scopus 로고    scopus 로고
    • Coiled coil and/or tether containing protein complexes and uses thereof
    • WO2011034605
    • Christensen EH, Eaton DL, Vendel AC, Wranik B. Coiled coil and/or tether containing protein complexes and uses thereof. WO2011034605. 2011
    • (2011)
    • Christensen, E.H.1    Eaton, D.L.2    Vendel, A.C.3    Wranik, B.4
  • 45
    • 77954225154 scopus 로고    scopus 로고
    • Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling
    • PMID:20444694
    • Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, et al. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 2010; 285:20850-9; PMID:20444694; http://dx.doi.org/10.1074/jbc.M110.113910
    • (2010) J Biol Chem , vol.285 , pp. 20850-20859
    • Jackman, J.1    Chen, Y.2    Huang, A.3    Moffat, B.4    Scheer, J.M.5    Leong, S.R.6
  • 46
    • 77954996067 scopus 로고    scopus 로고
    • VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist singlechain diabody
    • PMID:20576629
    • Igawa T, Tsunoda H, Kikuchi Y, Yoshida M, Tanaka M, Koga A, et al. VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist singlechain diabody. Protein Eng Des Sel 2010; 23:667-77; PMID:20576629; http://dx.doi.org/10.1093/protein/ gzq034
    • (2010) Protein Eng des Sel , vol.23 , pp. 667-677
    • Igawa, T.1    Tsunoda, H.2    Kikuchi, Y.3    Yoshida, M.4    Tanaka, M.5    Koga, A.6
  • 47
    • 79960592856 scopus 로고    scopus 로고
    • Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies
    • PMID:21690412
    • Schaefer W, Regula JT, Bähner M, Schanzer J, Croasdale R, Dürr H, et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A 2011; 108:11187-92; PMID:21690412; http://dx.doi.org/10.1073/pnas.1019002108
    • (2011) Proc Natl Acad Sci U S A , vol.108 , pp. 11187-11192
    • Schaefer, W.1    Regula, J.T.2    Bähner, M.3    Schanzer, J.4    Croasdale, R.5    Dürr, H.6
  • 48
    • 84891923917 scopus 로고    scopus 로고
    • Crossing over to bispecificity
    • Cain C. Crossing over to bispecificity. SciBX 2011; 4:1-4
    • (2011) SciBX , vol.4 , pp. 1-4
    • Cain, C.1
  • 49
    • 80053463397 scopus 로고    scopus 로고
    • A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis
    • PMID:21851472
    • Rennel ES, Regula JT, Harper SJ, Thomas M, Klein C, Bates DO. A human neutralizing antibody specific to Ang-2 inhibits ocular angiogenesis. Microcirculation 2011; 18:598-607; PMID:21851472; http://dx.doi.org/10.1111/j. 1549-8719.2011.00120.x
    • (2011) Microcirculation , vol.18 , pp. 598-607
    • Rennel, E.S.1    Regula, J.T.2    Harper, S.J.3    Thomas, M.4    Klein, C.5    Bates, D.O.6
  • 50
    • 84869815735 scopus 로고    scopus 로고
    • Readily isolated bispecific antibodies with native immunoglobulin format
    • WO2010151792
    • Davis S, Smith E, Macdonald D, Olson KL. Readily isolated bispecific antibodies with native immunoglobulin format. WO2010151792. 2011
    • (2011)
    • Davis, S.1    Smith, E.2    Macdonald, D.3    Olson, K.L.4
  • 51
    • 84869815268 scopus 로고    scopus 로고
    • Antibody Modification Method for Purifying Bispecific Antibody
    • WO2007114325
    • Igawa T, Tsunoda H. Antibody Modification Method For Purifying Bispecific Antibody. WO2007114325. 2011
    • (2011)
    • Igawa, T.1    Tsunoda, H.2
  • 52
    • 79957439772 scopus 로고    scopus 로고
    • Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target
    • PMID:21613623
    • Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, et al. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med 2011; 3:84ra44; PMID:21613623; http://dx.doi.org/10.1126/ scitranslmed.3002230
    • (2011) Sci Transl Med , vol.3
    • Yu, Y.J.1    Zhang, Y.2    Kenrick, M.3    Hoyte, K.4    Luk, W.5    Lu, Y.6
  • 53
    • 73149121904 scopus 로고    scopus 로고
    • Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys
    • PMID:19850673
    • Stubenrauch K, Wessels U, Regula JT, Kettenberger H, Schleypen J, Kohnert U. Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys. Drug Metab Dispos 2010; 38:84-91; PMID:19850673; http://dx.doi.org/10.1124/dmd.109.029751
    • (2010) Drug Metab Dispos , vol.38 , pp. 84-91
    • Stubenrauch, K.1    Wessels, U.2    Regula, J.T.3    Kettenberger, H.4    Schleypen, J.5    Kohnert, U.6
  • 54
    • 68449083226 scopus 로고    scopus 로고
    • Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo
    • PMID:19620983
    • Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767-71; PMID:19620983; http://dx.doi.org/10.1038/nbt.1553
    • (2009) Nat Biotechnol , vol.27 , pp. 767-771
    • Labrijn, A.F.1    Buijsse, A.O.2    Van Den Bremer, E.T.3    Verwilligen, A.Y.4    Bleeker, W.K.5    Thorpe, S.J.6
  • 57
    • 84862015979 scopus 로고    scopus 로고
    • Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair
    • PMID:22543237
    • Strop P, Ho WH, Boustany LM, Abdiche YN, Lindquist KC, Farias SE, et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol 2012; 420:204-19; PMID:22543237; http://dx.doi.org/10.1016/j.jmb.2012. 04.020
    • (2012) J Mol Biol , vol.420 , pp. 204-219
    • Strop, P.1    Ho, W.H.2    Boustany, L.M.3    Abdiche, Y.N.4    Lindquist, K.C.5    Farias, S.E.6
  • 58
    • 80555156163 scopus 로고    scopus 로고
    • Smarter drugs: A focus on pan-specific monoclonal antibodies
    • PMID:22050338
    • Fagète S, Fischer N. Smarter drugs: a focus on pan-specific monoclonal antibodies. BioDrugs 2011; 25:357-64; PMID:22050338; http://dx.doi.org/10.2165/11594690-000000000-00000
    • (2011) BioDrugs , vol.25 , pp. 357-364
    • Fagète, S.1    Fischer, N.2
  • 59
    • 77956940247 scopus 로고    scopus 로고
    • Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis
    • PMID:20644170
    • Buatois V, Fagète S, Magistrelli G, Chatel L, Fischer N, Kosco-Vilbois MH, et al. Pan-CC chemokine neutralization restricts splenocyte egress and reduces inflammation in a model of arthritis. J Immunol 2010; 185:2544-54; PMID:20644170; http://dx.doi.org/10.4049/jimmunol.1000182
    • (2010) J Immunol , vol.185 , pp. 2544-2554
    • Buatois, V.1    Fagète, S.2    Magistrelli, G.3    Chatel, L.4    Fischer, N.5    Kosco-Vilbois, M.H.6
  • 60
    • 33645819161 scopus 로고    scopus 로고
    • A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus
    • PMID:16581912
    • Alejo A, Ruiz-Argüello MB, Ho Y, Smith VP, Saraiva M, Alcami A. A chemokine-binding domain in the tumor necrosis factor receptor from variola (smallpox) virus. Proc Natl Acad Sci U S A 2006; 103:5995-6000; PMID:16581912; http://dx.doi.org/10.1073/pnas.0510462103
    • (2006) Proc Natl Acad Sci U S A , vol.103 , pp. 5995-6000
    • Alejo, A.1    Ruiz-Argüello, M.B.2    Ho, Y.3    Smith, V.P.4    Saraiva, M.5    Alcami, A.6
  • 61
    • 84855478513 scopus 로고    scopus 로고
    • Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry
    • PMID:22041899
    • Fagète S, Rousseau F, Magistrelli G, Gueneau F, Ravn U, Kosco-Vilbois MH, et al. Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. J Biol Chem 2012; 287:1458-67; PMID:22041899; http://dx.doi.org/10.1074/jbc. M111.253658
    • (2012) J Biol Chem , vol.287 , pp. 1458-1467
    • Fagète, S.1    Rousseau, F.2    Magistrelli, G.3    Gueneau, F.4    Ravn, U.5    Kosco-Vilbois, M.H.6
  • 62
    • 79955545620 scopus 로고    scopus 로고
    • High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity
    • PMID:21526167
    • Bostrom J, Haber L, Koenig P, Kelley RF, Fuh G. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity. PLoS One 2011; 6:e17887; PMID:21526167; http://dx.doi.org/10.1371/journal.pone.0017887
    • (2011) PLoS One , vol.6
    • Bostrom, J.1    Haber, L.2    Koenig, P.3    Kelley, R.F.4    Fuh, G.5
  • 63
    • 62849095162 scopus 로고    scopus 로고
    • Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site
    • PMID:19299620
    • Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610-4; PMID:19299620; http://dx.doi.org/10. 1126/science.1165480
    • (2009) Science , vol.323 , pp. 1610-1614
    • Bostrom, J.1    Yu, S.F.2    Kan, D.3    Appleton, B.A.4    Lee, C.V.5    Billeci, K.6
  • 64
    • 64949153511 scopus 로고    scopus 로고
    • Improving antibody binding affinity and specificity for therapeutic development.
    • xiii. PMID:19252851
    • Bostrom J, Lee CV, Haber L, Fuh G. Improving antibody binding affinity and specificity for therapeutic development. [xiii.]. Methods Mol Biol 2009; 525:353-76, xiii; PMID:19252851; http://dx.doi.org/10.1007/978-1-59745-554-1-19
    • (2009) Methods Mol Biol , vol.525
    • Bostrom, J.1    Lee, C.V.2    Haber, L.3    Fuh, G.4
  • 65
    • 80054765331 scopus 로고    scopus 로고
    • A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies
    • PMID:22014573
    • Schaefer G, Haber L, Crocker LM, Shia S, Shao L, Dowbenko D, et al. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 2011; 20:472-86; PMID:22014573; http://dx.doi.org/10.1016/j.ccr.2011.09.003
    • (2011) Cancer Cell , vol.20 , pp. 472-486
    • Schaefer, G.1    Haber, L.2    Crocker, L.M.3    Shia, S.4    Shao, L.5    Dowbenko, D.6
  • 66
    • 77954638589 scopus 로고    scopus 로고
    • Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties
    • PMID:20150180
    • Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschläger M, Antes B, et al. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel 2010; 23:289-97; PMID:20150180; http://dx.doi.org/10.1093/protein/gzq005
    • (2010) Protein Eng des Sel , vol.23 , pp. 289-297
    • Wozniak-Knopp, G.1    Bartl, S.2    Bauer, A.3    Mostageer, M.4    Woisetschläger, M.5    Antes, B.6
  • 67
    • 79952271693 scopus 로고    scopus 로고
    • Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth
    • PMID:21233403
    • Huang H, Lai JY, Do J, Liu D, Li L, Del Rosario J, et al. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth. Clin Cancer Res 2011; 17:1001-11; PMID:21233403; http://dx.doi.org/10.1158/1078-0432.CCR-10-2317
    • (2011) Clin Cancer Res , vol.17 , pp. 1001-1011
    • Huang, H.1    Lai, J.Y.2    Do, J.3    Liu, D.4    Li, L.5    Del Rosario, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.